ALZ-101
Alzheimer's Disease (Early)
Phase 1bActive
Key Facts
About Alzinova
Alzinova is a clinical-stage biotech focused on developing disease-modifying immunotherapies for Alzheimer's disease, one of the world's largest unmet medical needs. Its core differentiator is the AβCC Peptide™ platform, designed to precisely target toxic amyloid-beta oligomers, believed to be the primary drivers of neurodegeneration. The company has progressed its lead vaccine candidate, ALZ-101, into Phase 1b clinical trials and is publicly listed on Nasdaq First North Growth Market in Stockholm to fund its ambitious R&D. Alzinova's strategy hinges on validating its oligomer-specific hypothesis to potentially offer a safer and more effective therapeutic option than broader amyloid-targeting approaches.
View full company profile